| Non-Small Cell Lung Carcinoma
Xalkori vs Augtyro
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Xalkori vs Augtyro with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAugtyro has a higher rate of injection site reactions vs Xalkori based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Augtyro but not Xalkori, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Xalkori
Augtyro
At A Glance
Oral
Twice daily
ALK/ROS1 inhibitor
Oral
Once daily x14 days, then twice daily
ROS1/TRK inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Ki-1+ Anaplastic Large Cell Lymphoma
- Inflammatory Myofibroblastic Tumor
- Non-Small Cell Lung Carcinoma
- Solid Neoplasm
Dosing
Non-Small Cell Lung Carcinoma Adults: 250 mg orally twice daily until disease progression or unacceptable toxicity.
Ki-1+ Anaplastic Large Cell Lymphoma Pediatric patients 1 year of age and older and young adults: 280 mg/m2 orally twice daily (BSA-based dosing) until disease progression or unacceptable toxicity.
Inflammatory Myofibroblastic Tumor Adults: 250 mg orally twice daily; pediatric patients 1 year of age and older: 280 mg/m2 orally twice daily (BSA-based dosing), until disease progression or unacceptable toxicity.
Non-Small Cell Lung Carcinoma, Solid Neoplasm 160 mg orally once daily for 14 days, then increase to 160 mg twice daily, with or without food, until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) Vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, neuropathy.
Serious Hepatotoxicity, interstitial lung disease/pneumonitis, QT interval prolongation, bradycardia, severe visual loss, gastrointestinal toxicity (in pediatric/young adult ALCL or pediatric IMT patients).
Postmarketing Increased blood creatine phosphokinase.
Most common (>=20%) Dizziness, dysgeusia, peripheral neuropathy, constipation, dyspnea, fatigue, ataxia, cognitive impairment, muscular weakness, nausea.
Serious Pneumonia, dyspnea, pleural effusion, hypoxia.
Pharmacology
Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, ROS1, c-Met, and RON; it blocks ALK fusion protein-driven oncogenic signaling, inhibiting tumor cell proliferation and survival.
Repotrectinib is a kinase inhibitor of ROS1 and tropomyosin receptor tyrosine kinases (TRKA, TRKB, TRKC); fusion proteins containing these domains drive tumorigenic potential through hyperactivation of downstream signaling pathways leading to unconstrained cell proliferation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Xalkori
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Augtyro
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Xalkori
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Augtyro
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Xalkori
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Augtyro
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Augtyro.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
XalkoriView full Xalkori profile
AugtyroView full Augtyro profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.